Oral JAK inhibitor LEQSELVI (deuruxolitinib) approved by US FDA for severe alopecia areata treatment
LEQSELVI delivered statistically significant efficacy across two Phase 3 clinical trials
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.